Hims & Hers Health Surges to Fifth Most Traded Stock with $724.9 Million Volume

On May 6, 2025, Hims & Hers Health (HIMS) experienced a significant surge in trading volume, reaching $724.9 million, marking a 141.42% increase from the previous day. This substantial rise in trading volume positioned Hims & Hers as the fifth most traded stock of the day. The company's stock price also saw a notable increase of 18.12%, extending its winning streak to four consecutive days, with a cumulative gain of 49.46% over this period.

Hims & Hers Health reported a remarkable 111% year-over-year revenue growth in the first quarter of 2025, reaching $586 million. This significant increase in revenue was driven by a surge in demand for the company's health and wellness services, particularly in the areas of mental health, sexual health, dermatology, and primary care. The company's net income for the quarter was $49.5 million, while its adjusted EBITDA stood at $91.1 million, reflecting a strong financial performance.

Despite the impressive revenue growth, Hims & Hers' stock experienced a decline in after-hours trading due to second-quarter projections that fell short of analysts' expectations. The company forecasted Q1 revenue of $530 million to $550 million, which was lower than the $564 million anticipated by Wall Street analysts. Additionally, the company's subscriber base grew by 38% year-over-year to 2.37 million, but this figure also fell short of analysts' expectations of 2.42 million subscribers.

Hims & Hers Health has outlined ambitious growth strategies for the future, including expanding its service offerings and strategic partnerships. The company aims to achieve $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. To support this growth, Hims & Hers is focusing on personalized treatments, global expansion, and building on its partnerships with pharmaceutical companies and innovative leaders in diagnostic and preventative testing.

One of the key partnerships announced by Hims & Hers is with Novo Nordisk, which will allow the company to offer its subscribers access to the branded weight loss drug Wegovy at a discount through its online pharmacy, NovoCare Pharmacy. This partnership is expected to further strengthen Hims & Hers' position in the weight loss market, which has become one of its largest specialties in just 18 months.